Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer
Year: 2021
Type: article
Study design: Observational Study
Abstract: KRAS is the most commonly mutated oncogene in NSCLC and development of direct KRAS inhibitors has renewed interest in this molecular variant. Different KRAS mutations may represent a unique biologic context with different prognostic and therapeutic impact. We sought to characterize genomic landscapes of advanced, KRAS-mutated non–small cell lung cancer (NSCLC) in a large national cohort to help guide future therapeutic development. Molecular profiles of 17,095 NSCLC specimens were obtained using DNA next-generation sequencing of 592 genes (Caris Life Sciences) and classified on the basis of presence and subtype of KRAS mutations. Co-occurring genomic alterations, tumor mutational burden (TMB), and PD-L1 expression [22C3, tumor proportion score (TPS) score] were analyzed by KRAS mutation type. Across the cohort, 4,706 (27.5%) samples harbored a KRAS mutation. The most common subtype was G12C (40%), followed by G12V (19%) and G12D (15%). The prevalence of KRAS mutations was 37.2% among adenocarcinomas and 4.4% in squamous cell carcinomas. Rates of high TMB (≥10 mutations/Mb) and PD-L1 expression varied across KRAS mutation subtypes. KRAS G12C was the most likely to be PD-L1 positive (65.5% TPS ≥ 1%) and PD-L1 high (41.3% TPS ≥ 50%). STK11 was mutated in 8.6% of KRAS wild-type NSCLC but more frequent in KRAS-mutant NSCLC, with the highest rate in G13 (36.2%). TP53 mutations were more frequent in KRAS wild-type NSCLC (73.6%). KRAS mutation subtypes have different co-occurring mutations and a distinct genomic landscape. The clinical relevance of these differences in the context of specific therapeutic interventions warrants investigation.
Source: Molecular Cancer Therapeutics
Authors: Julia Judd(Conceptualization, Investigation, Visualization, Writing – original draft, Writing – review & editing), Nagla Abdel Karim(Conceptualization, Investigation, Writing – review & editing), Hina Khan(Conceptualization, Investigation, Writing – review & editing), Abdul Rafeh Naqash(Investigation, Writing – review & editing), Yasmine Baca(Data curation, Formal analysis, Software, Visualization), Joanne Xiu(Data curation, Formal analysis, Software, Validation, Visualization), Ari M. VanderWalde(Investigation, Writing – review & editing), Hirva Mamdani(Investigation, Writing – review & editing), Luis E. Raez(Investigation, Writing – review & editing), Misako Nagasaka(Investigation, Writing – review & editing), Sachin Gopalkrishna Pai(Investigation, Writing – review & editing), Mark A. Socinski(Investigation, Writing – review & editing), Jorge J. Nieva(Investigation, Writing – review & editing), Chul Kim(Investigation, Writing – review & editing), Antoinette J. Wozniak(Investigation, Writing – review & editing), Chukwuemeka Ikpeazu(Investigation, Writing – review & editing), Gilberto de Lima Lopes, Alexander I. Spira(Investigation, Writing – review & editing), W. Michael Korn(Investigation, Writing – review & editing), Edward S. Kim(Investigation, Writing – review & editing), Stephen V. Liu(Conceptualization, Investigation, Visualization, Writing – review & editing), Hossein Borghaei(Conceptualization, Investigation, Writing – review & editing)
Institutions: Fox Chase Cancer Center, Temple University Health System, Augusta University, Brown University, University of Oklahoma Medical Center, National Cancer Institute, OU Health Stephenson Cancer Center, University of Oklahoma, Caris Life Sciences (United States), Wayne State University, The Barbara Ann Karmanos Cancer Institute, Memorial Healthcare System, USA Mitchell Cancer Institute, University of South Alabama, AdventHealth Orlando, AdventHealth, University of Southern California, USC Norris Comprehensive Cancer Center, Georgetown University, Georgetown Lombardi Comprehensive Cancer Center, University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, University of Miami, Sylvester Comprehensive Cancer Center, Virginia Cancer Specialists, City Of Hope National Medical Center, City of Hope
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W3201087911
